Literature DB >> 19544381

Characterization and gene expression profiling in glioma cell lines with deletion of chromosome 19 before and after microcell-mediated restoration of normal human chromosome 19.

Kristen L Drucker1, Gaspar J Kitange, Thomas M Kollmeyer, Mark E Law, Sandra Passe, Amanda L Rynearson, Hilary Blair, Cheryl L Soderberg, Bruce W Morlan, Karla V Ballman, Caterina Giannini, Robert B Jenkins.   

Abstract

Nearly 10% of human gliomas are oligodendrogliomas. Deletion of chromosome arm 19q, often in conjunction with deletion of 1p, has been observed in 65-80% of these tumors. This has suggested the presence of a tumor suppressor gene located on the 19q arm. Chromosome 19 deletion is also of interest due to the better prognosis of patients with deletion, including longer survival and better response to chemotherapy, compared with patients without deletion. Two glioma cell lines with deletion of 19q were used for chromosome 19 microcell-mediated transfer, to assess the effect of replacing the deleted segment. Complementation with chromosome 19 significantly reduced the growth rate of the hybrid cells compared with the parental cell lines. Affymetrix U133 Plus 2.0 Gene Chip analysis was performed to measure and compare the expression of the chromosome 19 genes in the chromosome 19 hybrid cell lines to the parental cell line. Probes were considered significantly different when a P value <0.01 was seen in all of the cell line comparisons. Of 345 probes within the commonly deleted 19q region, seven genes (APOE, RCN3, FLJ10781, SAE1, STRN4, CCDC8, and BCL2L12) were identified as potential candidate genes. RT-PCR analysis of primary tumor specimens showed that several genes had significant differences when stratified by tumor morphology or deletion status. This suggests that one or more of these candidates may play a role in glioma formation or progression. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19544381      PMCID: PMC3190979          DOI: 10.1002/gcc.20688

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  38 in total

1.  Chromosome 18 suppresses the tumorigenicity of prostate cancer cells.

Authors:  S S Padalecki; T L Johnson-Pais; A M Killary; R J Leach
Journal:  Genes Chromosomes Cancer       Date:  2001-03       Impact factor: 5.006

2.  Suppression of tumorigenicity in the human prostate cancer cell line M12 via microcell-mediated restoration of chromosome 19.

Authors:  C Astbury; C K Jackson-Cook; S H Culp; T E Paisley; J L Ware
Journal:  Genes Chromosomes Cancer       Date:  2001-06       Impact factor: 5.006

3.  Screening of genomic imbalances in glioblastoma multiforme using high-resolution comparative genomic hybridization.

Authors:  Vladimíra Vranová; Eva Necesalová; Petr Kuglík; Pavel Cejpek; Martina Pesáková; Eva Budínská; Jirina Relichová; Renata Veselská
Journal:  Oncol Rep       Date:  2007-02       Impact factor: 3.906

4.  Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma.

Authors:  Alexander H Stegh; Hyunggee Kim; Robert M Bachoo; Kristin L Forloney; Jean Zhang; Harald Schulze; Kevin Park; Gregory J Hannon; Junying Yuan; David N Louis; Ronald A DePinho; Lynda Chin
Journal:  Genes Dev       Date:  2007-01-01       Impact factor: 11.361

5.  A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma.

Authors:  Robert B Jenkins; Hilary Blair; Karla V Ballman; Caterina Giannini; Robert M Arusell; Mark Law; Heather Flynn; Sandra Passe; Sara Felten; Paul D Brown; Edward G Shaw; Jan C Buckner
Journal:  Cancer Res       Date:  2006-10-15       Impact factor: 12.701

6.  Cell cycle arrest and astrocytic differentiation resulting from PTEN expression in glioma cells.

Authors:  J Adachi; K Ohbayashi; T Suzuki; T Sasaki
Journal:  J Neurosurg       Date:  1999-11       Impact factor: 5.115

7.  Increased SPARC expression promotes U87 glioblastoma invasion in vitro.

Authors:  W A Golembieski; S Ge; K Nelson; T Mikkelsen; S A Rempel
Journal:  Int J Dev Neurosci       Date:  1999 Aug-Oct       Impact factor: 2.457

8.  Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2.

Authors:  Audrey Rousseau; Catherine L Nutt; Rebecca A Betensky; A John Iafrate; Moonjoo Han; Keith L Ligon; David H Rowitch; David N Louis
Journal:  J Neuropathol Exp Neurol       Date:  2006-12       Impact factor: 3.685

Review 9.  Toward a molecular classification of the gliomas: histopathology, molecular genetics, and gene expression profiling.

Authors:  L S Caskey; G N Fuller; J M Bruner; W K Yung; R E Sawaya; E C Holland; W Zhang
Journal:  Histol Histopathol       Date:  2000-07       Impact factor: 2.303

10.  Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival.

Authors:  Lydia Quaye; Dimitra Dafou; Susan J Ramus; Honglin Song; Aleksandra Gentry-Maharaj; Aleksandra Gentry Maharaj; Maria Notaridou; Estrid Hogdall; Susanne Kruger Kjaer; Lise Christensen; Claus Hogdall; Douglas F Easton; Ian Jacobs; Usha Menon; Paul D P Pharoah; Simon A Gayther
Journal:  Hum Mol Genet       Date:  2009-03-06       Impact factor: 6.150

View more
  5 in total

1.  BCL2L12 is a novel biomarker for the prediction of short-term relapse in nasopharyngeal carcinoma.

Authors:  Ali Fendri; Christos K Kontos; Abdelmajid Khabir; Raja Mokdad-Gargouri; Andreas Scorilas
Journal:  Mol Med       Date:  2010-12-08       Impact factor: 6.354

2.  Pan-Cancer Analysis of the Oncogenic and Immunological Role of RCN3: A Potential Biomarker for Prognosis and Immunotherapy.

Authors:  Jian Ding; Yan Meng; Zelong Han; Xiaobei Luo; Xuxue Guo; Yiwen Li; Side Liu; Kangmin Zhuang
Journal:  Front Oncol       Date:  2022-05-16       Impact factor: 5.738

3.  Clinical significance and novel mechanism of action of kallikrein 6 in glioblastoma.

Authors:  Kristen L Drucker; Alex R Paulsen; Caterina Giannini; Paul A Decker; Sachiko I Blaber; Michael Blaber; Joon H Uhm; Brian P O'Neill; Robert B Jenkins; Isobel A Scarisbrick
Journal:  Neuro Oncol       Date:  2013-01-10       Impact factor: 12.300

4.  Regulation of mRNA abundance by polypyrimidine tract-binding protein-controlled alternate 5' splice site choice.

Authors:  Fursham M Hamid; Eugene V Makeyev
Journal:  PLoS Genet       Date:  2014-11-06       Impact factor: 5.917

5.  Global extracellular vesicle proteomic signature defines U87-MG glioma cell hypoxic status with potential implications for non-invasive diagnostics.

Authors:  Vineesh Indira Chandran; Charlotte Welinder; Kelin Gonçalves de Oliveira; Myriam Cerezo-Magaña; Ann-Sofie Månsson; Maria C Johansson; Gyorgy Marko-Varga; Mattias Belting
Journal:  J Neurooncol       Date:  2019-08-14       Impact factor: 4.130

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.